232 related articles for article (PubMed ID: 26013475)
1. Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study.
Giacomet V; Nannini P; Vigano A; Erba P; Benincaso A; Bedogni G; Cattaneo D; Falvella FS; Zuccotti GV
Clin Drug Investig; 2015 Jul; 35(7):419-26. PubMed ID: 26013475
[TBL] [Abstract][Full Text] [Related]
2. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
Viganò A; Bedogni G; Manfredini V; Giacomet V; Cerini C; di Nello F; Penagini F; Caprio C; Zuccotti GV
Clin Drug Investig; 2011; 31(6):407-15. PubMed ID: 21528939
[TBL] [Abstract][Full Text] [Related]
3. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
4. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
5. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
8. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
9. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
[TBL] [Abstract][Full Text] [Related]
10. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
[TBL] [Abstract][Full Text] [Related]
11. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
Marcelin JR; Berg ML; Tan EM; Amer H; Cummins NW; Rizza SA
PLoS One; 2016; 11(2):e0149562. PubMed ID: 26872144
[TBL] [Abstract][Full Text] [Related]
12. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
13. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
14. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
15. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
19. Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Bregigeon S; Solas C; Faucher O; Obry-Roguet V; Tamalet C; Poizot-Martin I
Antivir Ther; 2017; 22(6):529-533. PubMed ID: 28195560
[TBL] [Abstract][Full Text] [Related]
20. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]